SpaMedica Ltd.

SpaMedica Ltd. specializes in providing NHS-funded cataract surgeries, enhancing patient access to vital eye care services. The company is recognized as the largest independent provider of these surgeries in the UK, focusing on quality and efficiency. Founded in 2008, SpaMedica Ltd.

is based in Bolton, UK, and operates as an independent provider of NHS cataract surgeries. The company has maintained its focus on eye care services without significant pivots in strategy. Led by CEOs Paul Stout and Richard Woodward, SpaMedica has completed two deals, with the most recent occurring on March 17, 2020. In that deal, it was acquired by Ober Scharrer Gruppe GmbH from CBPE Capital.

SpaMedica primarily offers NHS cataract surgery as its core service, positioning itself as the largest independent provider of this essential healthcare intervention in the UK. With a focus on improving the quality of life for patients suffering from cataracts, SpaMedica's services include YAG laser capsulotomy and treatment for age-related macular degeneration (AMD), among other eye care solutions. The company aims to reduce waiting times for surgeries, boasting an impressive average wait time of four weeks for treatment, which addresses a critical need within the NHS framework. SpaMedica caters to a broad range of patients, from those seeking immediate surgical intervention to individuals requiring follow-up care.

The company operates across the UK, with over 60 hospitals strategically located to ensure accessibility for patients nationwide. In 2023, SpaMedica reported revenues of USD 349. 68 mn and an EBITDA of USD 126. 38 mn.

The revenue model is primarily structured around NHS-funded cataract surgeries provided at no cost to patients, ensuring high accessibility for those in need of eye care services. Transactions typically occur through partnerships with the NHS, allowing for a streamlined process for patients referred to SpaMedica by primary care providers. The company also engages in B2B relationships with healthcare professionals, providing resources and support for optometrists and other eye care specialists involved in patient referrals. SpaMedica has received numerous five-star reviews, underscoring its reputation within the healthcare community.

Looking ahead, SpaMedica plans to expand its network of hospitals to enhance patient accessibility further. This includes targeting new regions within the UK, specifically aiming for expansion initiatives to be implemented by the end of 2024. The recent acquisition by Ober Scharrer Gruppe GmbH will enable the company to leverage additional resources and support for these growth initiatives. SpaMedica is also exploring new eye care services that could be integrated into its offering, although specific products and launch dates have not been disclosed.